Objectives:Using phosphodiesterase type 5 (PDE5) inhibitors in lower urinary tract symptoms (LUTS) patients still continues to draw attention.
Despite clinical improvements in patients, it is still debatable whether urinary flow rates are increased or not. The aim of this study was to evaluate acute effects of sildenafil, a PDE5 inhibitor, on uroflowmetry parameters.
Methods:110 males, who have applied to our outpatient clinics, and had no history of alpha blocker and PDE5 inhibitor use, are included into study. Two uroflowmetries were performed within 24-72 hours without any treatments. Participants received 50 mg sildenafil at their third visits and uroflowmetry was repeated after 2 hours. A total of 102 males were included in analysis and baseline uroflowmetry values were compared with values obtained after sildenafil use.
Findings:Mean age of 102 participants, who have attended all three visits (92.7%), was 52.1 ± 12.2 years. Mean of baseline maximal flow rate (Qmax) values were 17.1 ± 5.1 ml/sec, mean of Qmax after sildenafil was 18.2 ± 5.1 ml/sec; average flow rates (Qave) values at the baseline and after sildenafil were 9.5 ± 3.5 and 9.9 ± 3.5 ml/sec, respectively. Mean of postvoid residual urine (PVR) volume for baseline and after sildenafil were 31.2 ± 20.1 and 27.7 ± 18.4 ml, respectively. Statistically significant difference is determined between baseline and post-sildenafil values in terms of Qave and PVR values.
Conclusion: Results of this study suggest that sildenafil has effect on uroflowmetric parameters on acute period.
Written by:
Oztürk MI, Koca O, Sertkaya Z, Keles MO, Kaya C, Karaman MI. Are you the author?
Reference: J Androl. 2012 Apr 5. Epub ahead of print.
doi: 10.2164/jandrol.111.015776
PubMed Abstract
PMID: 22492839
UroToday.com Erectile Dysfunction Section
